HomeCompareIPSEF vs FCPT

IPSEF vs FCPT: Dividend Comparison 2026

IPSEF yields 1.45% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FCPT wins by $7.9K in total portfolio value
10 years
IPSEF
IPSEF
● Live price
1.45%
Share price
$113.13
Annual div
$1.64
5Y div CAGR
38.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.2K
Annual income
$6,651.20
Full IPSEF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — IPSEF vs FCPT

📍 FCPT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPSEFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPSEF + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPSEF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPSEF
Annual income on $10K today (after 15% tax)
$123.06/yr
After 10yr DRIP, annual income (after tax)
$5,653.52/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, IPSEF beats the other by $744.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPSEF + FCPT for your $10,000?

IPSEF: 50%FCPT: 50%
100% FCPT50/50100% IPSEF
Portfolio after 10yr
$45.1K
Annual income
$6,213.24/yr
Blended yield
13.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

IPSEF
No analyst data
Altman Z
3.8
Piotroski
7/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPSEF buys
0
FCPT buys
0
No recent congressional trades found for IPSEF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPSEFFCPT
Forward yield1.45%6.05%
Annual dividend / share$1.64$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38.6%15.8%
Portfolio after 10y$41.2K$49.1K
Annual income after 10y$6,651.20$5,775.28
Total dividends collected$18.8K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: IPSEF vs FCPT ($10,000, DRIP)

YearIPSEF PortfolioIPSEF Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$10,901$200.65$11,401$700.92$500.00FCPT
2$11,947$283.32$13,064$864.84$1.1KFCPT
3$13,186$402.22$15,051$1,072.48$1.9KFCPT
4$14,684$575.02$17,442$1,337.22$2.8KFCPT
5$16,541$829.46$20,340$1,677.08$3.8KFCPT
6$18,909$1,210.33$23,880$2,116.57$5.0KFCPT
7$22,025$1,792.24$28,241$2,689.36$6.2KFCPT
8$26,271$2,704.08$33,660$3,442.07$7.4KFCPT
9$32,288$4,177.89$40,456$4,439.95$8.2KFCPT
10$41,199$6,651.20$49,063$5,775.28$7.9KFCPT

IPSEF vs FCPT: Complete Analysis 2026

IPSEFStock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Full IPSEF Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this IPSEF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPSEF vs SCHDIPSEF vs JEPIIPSEF vs OIPSEF vs KOIPSEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.